Patents by Inventor Ana C. Pastini
Ana C. Pastini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10695336Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: February 6, 2019Date of Patent: June 30, 2020Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Publication number: 20190167654Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: ApplicationFiled: February 6, 2019Publication date: June 6, 2019Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: HERNAN D. BENEDETTI, CRISTIAN R. FRANCO, GUIDO S. BIGATTI, JOAQUINA FAOUR, ANA C. PASTINI
-
Patent number: 10265308Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: July 21, 2017Date of Patent: April 23, 2019Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Publication number: 20180221360Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: ApplicationFiled: July 21, 2017Publication date: August 9, 2018Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: HERNAN D. BENEDETTI, CRISTIAN R. FRANCO, GUIDO S. BIGATTI, JOAQUINA FAOUR, ANA C. PASTINI
-
Patent number: 9855258Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: June 15, 2017Date of Patent: January 2, 2018Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Patent number: 9833412Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: GrantFiled: February 24, 2014Date of Patent: December 5, 2017Assignee: Osmotica Kereskedelmi es Szolgaltato KFTInventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Patent number: 9827234Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: June 15, 2017Date of Patent: November 28, 2017Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Patent number: 9707217Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.Type: GrantFiled: February 3, 2017Date of Patent: July 18, 2017Assignee: Osmotica Kereskedelmi es Szolgaltato KFTInventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
-
Publication number: 20140302141Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: February 24, 2014Publication date: October 9, 2014Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
-
Patent number: 8685451Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: GrantFiled: June 18, 2008Date of Patent: April 1, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Patent number: 8637080Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: GrantFiled: June 25, 2008Date of Patent: January 28, 2014Assignee: Osmotica Kereskedelmi és Szolgáltató, KFTInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Patent number: 8574626Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: GrantFiled: July 18, 2012Date of Patent: November 5, 2013Assignee: Osmotica Kereskedelmi és Szolgáltató KFTInventors: Juan A. Vergez, Joaquina Faour, Ana C. Pastini, Guido S. Bigatti, Glenn A. Meyer, Ethel C. Feleder, Marcelo A. Ricci, Marcelo A. Coppari, Marcelo F. Befumo
-
Publication number: 20130115249Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Joaquina FAOUR, Ana C. PASTINI, Guido S. BIGATTI, Glenn A. MEYER, Ethel C. FELEDER, Marcelo A. RICCI, Marcelo A. COPPARI, Marcelo F. BEFUMO
-
Patent number: 8293799Abstract: The osmotic devices of the present invention include a single core comprising a salt of a drug and an osmotic salt, wherein the drug salt and the osmotic salt have a common ion. The release rate of the active drug is reduced, and the release profile of the active drug is modified, from a first order release profile to a zero order, pseudo-zero order, or sigmoidal release profile, by increasing the amount of the sodium chloride in the core of the device. In one embodiment the sodium chloride is used to modify a controlled release profile to a delayed and controlled release profile.Type: GrantFiled: December 13, 2004Date of Patent: October 23, 2012Assignee: Osmotica Keresleedelmo és Szolgáltató KFTInventors: Ethel C. Feleder, Glenn A. Meyer, Marcelo A. Ricci, Joaquina Faour, Ana C. Pastini, Marcelo F. Befumo
-
Publication number: 20090004229Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicant: OSMOTICA COSTA RICA SOCIEDAD ANONIMAInventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
-
Publication number: 20080299197Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.Type: ApplicationFiled: June 18, 2008Publication date: December 4, 2008Applicant: OSMOTICA CORP.Inventors: Fernando G. Toneguzzo, Glenn A. Meyer, Marcelo A. Ricci, Marcelo A. Coppari, Ana C. Pastini, Gustavo A. Fischbein
-
Publication number: 20080175909Abstract: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-Alzheimer's or an anti-Parkinson's drug in a rapid release external coat. Memantine is used as an anti-Alzheimer's drug or an anti-Parkinson's drug. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather than compression-coated onto the device. The device is useful for the treatment of symptoms associate with Alzheimer's disease and/or Parkinson's disease patients. The device and method can also be used to treat or ameliorate other symptoms associated with Alzheimer's disease, Parkinson's disease or any other neurological disorder. Other dosage forms that provide a controlled, sustained or extended release of venlafaxine in combination with a rapid or immediate release of memantine are useful in the invention.Type: ApplicationFiled: October 10, 2007Publication date: July 24, 2008Applicant: OSMOTICA CORP.Inventors: Juan A. VERGEZ, Joaquina FAOUR, Marcelo A. RICCI, Ana C. PASTINI